Cartesian reports Q3 2026 results, AURORA Phase 3 data due in 1Q27
Cartesian said its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis remains on track for a 1Q27 readout, with a BLA filing planned for mid-2027.
Cartesian Therapeutics reported third quarter 2026 financial results and a business update on November 5, 2026. The Phase 3 AURORA trial, a randomized, double-blind, placebo-controlled study of Descartes-08 versus placebo in approximately 100 patients with acetylcholine receptor autoantibody positive myasthenia gravis, is designed with a primary endpoint assessing the proportion of patients achieving a three-point or greater improvement in MG-ADL score at Month 4 compared to placebo.1 The company said data readout is expected in 1Q27, with a BLA filing planned for mid-2027.
Cartesian also disclosed retreatment data presented in September 2026. The analysis included five patients with MG who had completed a full course of Descartes-08 in the Phase 2 portion of the trial and relapsed after 12 months; they were retreated a median of 16.6 months after their initial course, and at Month 12 following retreatment achieved a mean MG-ADL reduction of 6.6 points from baseline.1 The company said consistent safety data observed to date supports potential retreatment of Descartes-08 following recurrence of MG symptoms, with no new safety signals.1
On other programs, Cartesian plans to evaluate a subset of patients from the Phase 2 TRITON myositis trial to determine a potential path to a pivotal trial.1 Separately, enrollment remains ongoing in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including juvenile dermatomyositis.1 Data from both TRITON and HELIOS are expected in 1H27, the company said.
Cartesian's partnership with WestGene continues to progress through preclinical development, with in vitro testing showing WestGene's targeted lipid nanoparticles generated CAR-T cells in a dose-dependent manner; Cartesian plans to move the program into clinical development after completing preclinical testing.1
On finances, cash, cash equivalents and restricted cash totaled $124.7 million as of September 30, 2026, including an initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the company's at-the-market offering program.1 The company said current cash resources are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.